Skip to main content

elmiron hcp logo

Prescribing Information

FOR US HEALTHCARE PROFESSIONALS

IC Connect Registration Logo

JanssenMD Logo

  • ABOUT INTERSTITIAL CYSTITIS
    • IC Overview
    • Patient Evaluation
    • Mimicking Conditions
  • ABOUT ELMIRON®
    • ELMIRON® and IC
    • Proven Efficacy
    • Dosing Information
  • PATIENT SUPPORT
    • Patient Counseling
    • Counseling Materials
    • Follow Up
    • Managed Care
    • Patient Savings
    • Additional Resources
  • PRACTICE RESOURCES
    • IC Connect
    • Treatment Journey Tool
  • Important Safety Information
  • Prescribing Information
  • Contact Us
  • Patients
  • For US Healthcare Professionals Only

Sitemap

  • Home
  • About Interstitial Cystitis
    • IC Overview
    • Patient Evaluation
    • Mimicking Conditions
  • About ELMIRON®
    • ELMIRON® and IC
    • Proven Efficacy
    • Dosing Information
  • Patient Support
    • Patient Counseling
    • Counseling Materials
    • Follow Up
    • Managed Care
    • Patient Savings
    • Additional Resources
  • Practice Resources
    • IC Connect
    • Treatment Journey Tool
  • Important Safety Information
  • Prescribing Information
  • Patients
  • IC Connect Registration
  • Medical Information
  • Legal Notice
  • Privacy Policy
  • Contact Us
  • Sitemap

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

  • Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.
  • Anticoagulant Activity: ELMIRON® is a weak anticoagulant (blood thinner) which may increase bleeding. Patients undergoing invasive surgery or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to anticoagulant therapy or high doses of anti-inflammatory drugs) should be evaluated for the risk of hemorrhage.
  • Alopecia: In clinical trials of ELMIRON®, alopecia began within the first 4 weeks of treatment. Ninety-seven percent (97%) of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp.
  • Use in Pregnancy: ELMIRON® is a Pregnancy Category B drug.
  • Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), and dizziness (1%).


Please see full Prescribing Information for ELMIRON®. 

02E10016P

ELMIRON® is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

ELMIRON® is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

Janssen

© Janssen Pharmaceuticals, Inc. 2017. All rights reserved.

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center | Sitemap | Sitemap 

Last Updated January 15, 2018 020256-171221

The information contained in this section of the site is intended for US healthcare professionals only.